Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
P/S ratio for Prothena Corporation plc (PRTA)
P/S ratio as of 2023: 21.17
According to Prothena Corporation plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 21.17. At the end of 2022 the company had a P/S ratio of 52.94.
P/S ratio history for Prothena Corporation plc from 2010 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 21.17 |
| 2022 | 52.94 |
| 2021 | 10.89 |
| 2020 | 561.99 |
| 2019 | 775.59 |
| 2018 | 426.66 |
| 2017 | 51.30 |
| 2016 | 1601.64 |
| 2015 | 1285.32 |
| 2014 | 10.07 |
| 2013 | 730.28 |
| 2012 | 40.24 |
| 2011 | 251.06 |
| 2010 | 102.40 |